38results about How to "The composition is less" patented technology

Hemostatic agents and devices are made from oxidized cellulose fiber, the oxidized cellulose having a carboxylation content increased by the action of nitrogen dioxide on virgin cellulose fiber. A composition may be incorporated into the oxidized cellulose fiber to cause a pharmacological effect on a wound to which the hemostatic agents and devices are applied. When applied, the oxidized cellulose fiber causes blood emanating from the wound to clot. The oxidized cellulose fiber can either be resorbed into the wound or removed from the wound after healing. A hemostatic bandage includes a pad of unwoven oxidized cellulose fibers mounted on a substrate. Methods of arresting a flow of blood emanating from a wound using such devices are also disclosed. Methods of fabricating oxidized cellulose are also disclosed.

Disclosed are hydrophobic finish compositions and cementitious articles made with the hydrophobic finish compositions. In some embodiments, the article is a waterproof gypsum panel surface reinforced with inorganic mineral fibers that face a flexible and hydrophobic cementitious finish possessing beneficial waterproofing properties. These waterproof gypsum panels have many uses, such as, tile backer board in wet or dry areas of buildings, exterior weather barrier panel for use as exterior sheathing, interior wall and ceiling, and roof cover board having water durability and low surface absorption. The flexible and hydrophobic cementitious finish can include fly ash, film-forming polymer, preferably silane compound (e.g., alkyl alkoxysilane), an extended flow time retention agent including either one or more carboxylic acids, salts of carboxylic acids, or mixtures thereof, and other optional additives. Preferably a pre-coated non-woven glass fiber mat is employed to provide the inorganic mineral fibers for the surface reinforcement.

The invention discloses synergistic combinations of surfactants blends and cleaning composition. In certain embodiments a surfactant system is disclosed which includes extended anionic surfactants, linker surfactants, and a multiply charged cation component. This system forms emulsions with, and can remove greasy and oily stains, even those comprised of non-trans fats. In another embodiment anionic surfactants are combined with a solvent, and amine oxide to remove sunscreen stains. The compositions may be used alone, as a pre-spotter or other pre-treatment or as a part of a soft surface or hard surface cleaning composition.

In a sintered body of low temperature cofired ceramic constituting ceramic layers of a multilayer ceramic substrate provided with external conductor films, which is obtained by sintering a non-glass low temperature cofired ceramic material, respective crystalline phases of quartz, alumina, and fresnoite are deposited. The ceramic layers are, because of being in the form of a sintered body of non-glass low temperature cofired ceramic, less likely to fluctuate in composition, and the multilayer ceramic substrate can be thus inexpensively and easily manufactured therefrom. In addition, the ceramic layers have the above-mentioned respective crystalline phases deposited therein, and thus have a high joint strength with the external conductor films, and moreover, the sintered body itself has a high fracture toughness value.

The invention relates to an external pharmaceutical composition preparation with functions of resisting inflammation, reducing swelling and relieving pain, which is characterized in that the preparation is prepared by the following effective component raw materials in weight percent of the whole preparation: 0.01 to 20 percent of escin and/or pharmaceutically acceptable salt thereof, 0.01 to 10 percent of diclofenac or pharmaceutically acceptable salt thereof, and the balance being accessories. The external pharmaceutical composition can be made into any pharmaceutically acceptable external dosage form. The preparation can be used for treating symptoms, such as arthralgia, hyperosteogeny, gout, neuropathic pain, injuries from falls, chronic strain diseases and various closed injuries, and the like, and has strong practicability.

The invention relates to an external-use pharmaceutical composition preparation used for resisting inflammation, reducing swelling and relieving pain, which is characterized in that: the raw materials of active ingredients of the prepared medicine and the weight percentages thereof account for the whole preparation are: 0.01 percent to 20 percent of seed extractions of one or a plurality of aesculus wilsonii rehd, horse chestnut, aesculus chinensis bge.var.chekiangensis(Hu et Fang) Fang, European horse-chestnut and Japanese horse chestnut, 0.0001 percent to 20 percent of root extractions of one or a plurality of aconite, aconitum kusnezoffii maxim, aconitum karakolicum, A. sinomontanum, pendulous monkshood root, aconitum vilmorinianum, aconitum austroyunnanense, acomtum hemsleyanum pritz, root of short stalk monkshood radix aconiti brachypodi, scaphoidhelmet monkshood herb, aconitum tanguticum and aconitum nagarum var.lasiandrum, and others are accessories. The invention also discloses another external-use pharmaceutical composition preparation used for resisting inflammation, reducing swelling and relieving pain. The active ingredients of the prepared medicines are seed extractions of one or a plurality of aesculus wilsonii rehd, horse chestnut, aesculus chinensis bge.var.chekiangensis(Hu et Fang)Fang, European horse-chestnut and Japanese horse chestnut, root extractions of one or more than one of aconite, aconitum kusnezoffii maxim, aconitum karakolicum, A. sinomontanum, pendulous monkshood root, aconitum vilmorinianum, aconitum austroyunnanense, acomtum hemsleyanum pritz, root of short stalk monkshood radix aconiti brachypodi, scaphoidhelmet monkshood herb, aconitum tanguticum and aconitum nagarum var.lasiandrum, and one or a plurality of holly extraction, capsicum extraction, corn mint extraction, eucalyptus globules extraction, camphor, borneol and musk.

Various embodiments disclosed relate to absorbent clumping animal litter compositions, and to methods of using and making the same. In some embodiments, the present invention provides an absorbent clumping animal litter composition including an absorbent component and a pumice component.

The invention discloses a Chinese patent medicine for treating globus hysteriocus. The Chinese patent medicine for treating globus hysteriocus comprises the following raw material medicines in parts by weight: 10-100 parts of citron, 10-100 parts of nutgrass galingale rhizome, 100-600 parts of common fennel, 100-500 parts of anise, 10-400 parts of pepper and 10-100 parts of walnut kernel, and also comprises the following auxiliary materials in parts by weight: 100-400 parts of sugar candy, 100-600 parts of white sugar, 100-1,000 parts of black sugar and 300-1,000 parts of balm. The Chinese patent medicine for treating globus hysteriocus has the advantages of less raw material components, scientific matching, no toxic or side effect and synergistic effect between every two medicines; and the globus hysteriocus can be substantially cured. The Chinese patent medicine has an obvious effect on the treatment of the globus hysteriocus; the cure rate of the Chinese patent medicine reaches over 80 percent; and the effectiveness ratio reaches over 96 percent. Through the Chinese patent medicine, the defects of low probability of radical cure, long treatment time and high cost existing in the conventional medicament for treating the globus hysteriocus are overcome.

Tellurium compound nanoparticles, including: an element M¹ where M¹ is at least one element selected from Cu, Ag, and Au; an element M² where M² is at least one element selected from B, Al, Ga, and In; Te; and optionally an element M³ where M³ is at least one element selected from Zn, Cd, and Hg; wherein a crystal structure of the tellurium compound nanoparticles is a hexagonal system, the tellurium compound nanoparticles are of a rod shape and have an average short-axis length of 5.5 nm or less, and when irradiated with light at a wavelength in a range of 350 nm to 1,000 nm, the tellurium compound nanoparticles emit photoluminescence having a wavelength longer than the wavelength of the irradiation light.